Galmed Pharmaceuticals Introduces Innovative Blood Markers for Aramchol, Leading SCD1 Inhibitor in Clinical Trials Galmed Pharmaceuticals presents new pharmacodynamic blood markers for Aramchol, enhancing understanding of its effects and potential in treating various diseases.

Galmed Pharmaceuticals Introduces Innovative Blood Markers for Aramchol, Leading SCD1 Inhibitor in Clinical Trials #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #Blood_Markers